MWNA
SGTX

Marshall Wace North America’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Marshall Wace North America’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,001
Closed -$1.25M – 1864
2020
Q4 		$1.25M Buy
+2,001
New +$908K 0.01% 884

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's SGTX Position: Q1 2021 in Review

Marshall Wace North America sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2021, closing a stake of 2,001 shares — an estimated $1.25M sold.

Marshall Wace North America first reported a position in SGTX in Q4 2020 and held it in 1 quarter. The position peaked at $1.25M in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q1 2021.

  • Marshall Wace North America reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 2,001 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.25M.
  • Marshall Wace North America first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Marshall Wace North America's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.25M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.